Director, Respiratory Biologics - Global & Health Outcomes Research

Position Summary

For drugs to be successful, there must be robust health outcomes data to support launch optimization, reimbursement and maintain market position. Specifically, evidence must be maintained throughout the product lifecycle as standard of care changes, new competitors are introduced, and patents expire on existing competitors. The landscape is evolving quickly as trials demonstrating efficacy in an area of unmet need may receive expedited review, or orphan product status designation which affects both GSK and competitors launch timelines and approval requirements.

More and more of our customers are developing sophisticated internal health outcomes capabilities and access to real world data that can be used to better understand unmet needs and real‑world effectiveness of our medicines. We need to better understand how our customers define value and to effectively collaborate with them to ensure we are generating value evidence data that includes real world evidence and cost‑effectiveness analysis that is impactful for payers, health systems, providers, and patients.

The role of Director is critical to achieving this ambition by supporting asset teams to ensure that each medicine GSK brings to market is supported by scientifically credible, high quality evidence that drives competitiveness and strong evidence‑based product positioning, value propositions and value‑based pricing. The role is critical to support the alignment of evidence with evidentiary requirements of customers responsible for marketing authorization, recommendation and reimbursement leading to successful patient access, product use and commercial success.

The role will report directly into the Senior Director, Global Real‑World Evidence & Health Outcomes Research Lead for the Respiratory Biologics portfolio and will have expertise in real‑world evidence and other non‑interventional study methods. The role is expected to have a cross‑indication remit, supporting launch of a fast‑moving high priority program. The Director will be accountable for engaging closely with global and country level data generation partners, and will actively support data generation planning, study design, execution, translation and dissemination across indications for the asset.

• Plan, design and execute RWE and qualitative research studies for a high priority asset and manage timelines, deliverables and budget. Assure quality of deliverables, including review and sign‑off of project specifications, protocols, data analysis plans, final study reports, abstracts, posters and manuscripts, and adherence to SOPs.
• Ensure alignment of local data generation efforts with the data generation plan and enable effective global‑local information sharing on data generation studies.
• Build strong working relationships with stakeholder groups across countries, medical, market access, R&D and commercial to ensure strategic alignment and optimal cross‑functional collaboration and communication.

This role will provide you the opportunity to lead key activities to progress your career. The responsibilities include the above activities and the opportunity to work with global data generation partners to shape evidence strategy.

This role is hybrid, blending remote and in‑office work to support collaboration and flexibility. Candidates must be located in the United States and able to travel as needed.

• Masters in health outcomes, patient‑reported outcomes, health economics, epidemiology, pharmacy, health or life sciences.
• 10+ years’ experience working in pharmaceutical industry, preferably in a multi‑national company.
• Experience with evidence generation planning and workshop development.
• Experience developing detailed project and program plans.
• Experience delivering studies and related communications to the matrix in a fast‑paced environment.
• Experience with a variety of study designs, i.e., RWE studies including prospective, cross‑sectional and retrospective cohort studies. Must have experience with patient‑reported outcomes research.
• Knowledge of the diversity and complexity of healthcare markets, health…